I. Cabalar

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

R. Marcus, D. Furst, K. Dao, 2019, Arthritis Care & Research.

A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

F. Miller, P. Plotz, M. Harris-Love, 2017, Seminars in arthritis and rheumatism.

Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

P. Lachenbruch, B. Myones, B. Feldman, 2009, Arthritis and rheumatism.

Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis.

D. Koziol, F. Miller, H. Cintas, 2009, Rheumatology.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

D. Furst, K. Dao, M. Rosen, 2019, Arthritis care & research.